regulatory
confidence high
sentiment positive
materiality 0.75
FDA grants QIDP designation to Armata's AP-SA02 for S. aureus bacteremia
Armata Pharmaceuticals, Inc.
- AP-SA02 receives QIDP for intravenous adjunct treatment of complicated MSSA/MRSA bacteremia.
- QIDP provides five-year Hatch-Waxman market exclusivity extension and eligibility for Fast Track.
- CEO Dr. Deborah Birx says Phase 3 superiority study planned to start in H2 2026.
- Company intends to submit a request for Fast Track Designation for AP-SA02 to FDA.